抗白血病细胞铁蛋白抗血清作为恶性肿瘤的诊断工具。

Antiserum against leukemia cell ferritin as a diagnostic tool for malignant neoplasms.

作者信息

Mori W, Asakawa H, Taguchi T

出版信息

J Natl Cancer Inst. 1975 Sep;55(3):513-8. doi: 10.1093/jnci/55.3.513.

DOI:10.1093/jnci/55.3.513

Abstract

The specific antiserum against a type of ferritin that is especially common to leukemia cells and the placenta was used to test, by countercurrent immunoelectrophoresis, sera from humans with various diseases. The best results were obtained with leukemia; patients with chronic myelogenous leukemia in blastic phase, acute myelogenous leukemia, lymphogenous leukemia, and unclassifiable juvenile leukemia frequently showed a positive reaction, but patients with chronic myelogenous leukemia in static phase did not. The average incidence of positive reaction among all leukemia patients was 54.0%. Patients with other malignant tumors (i.e., multiple myeloma, malignant lymphoma and carcinomas of the stomach, rectum, and liver) also often showed a positive reaction. The average incidence of positive reaction among all the patients with malignant diseases of the hematopoietic system, except for leukemia, was 34.3%, and that among patients with nonhematologic malignant neoplasms was 36.8%. However, the incidence of a positive reaction in patients with benign diseases and healthy individuals was less than 3%.

摘要

一种针对白血病细胞和胎盘特别常见的铁蛋白类型的特异性抗血清，通过对流免疫电泳用于检测患有各种疾病的人的血清。白血病患者的检测结果最佳；处于原始细胞期的慢性粒细胞白血病、急性粒细胞白血病、淋巴细胞白血病和无法分类的幼年型白血病患者经常呈阳性反应，但处于静止期的慢性粒细胞白血病患者则没有。所有白血病患者中阳性反应的平均发生率为54.0%。患有其他恶性肿瘤（即多发性骨髓瘤、恶性淋巴瘤以及胃癌、直肠癌和肝癌）的患者也经常呈阳性反应。除白血病外，所有造血系统恶性疾病患者中阳性反应的平均发生率为34.3%，非血液系统恶性肿瘤患者中为36.8%。然而，良性疾病患者和健康个体中阳性反应的发生率低于3%。